Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov;51(11):840-846.
doi: 10.1111/cup.14682. Epub 2024 Jul 15.

Case of a CIC::DUX4 fusion gene in a vascular neoplasm extends the spectrum of CIC-rearranged sarcomas

William R Jeck  1 , Sarah Rapisardo  1 , Barbara A Anderson  1 , Peter Hendrickson  2 , George Jour  3 , Richard F Riedel  4 , Brian E Brigman  5 , Rami N Al-Rohil  1
Affiliations
Case Reports

Case of a CIC::DUX4 fusion gene in a vascular neoplasm extends the spectrum of CIC-rearranged sarcomas

William R Jeck et al. J Cutan Pathol. 2024 Nov.

Abstract

CIC-rearranged sarcomas comprise a group of exceptionally aggressive round-cell sarcomas. These tumors most commonly demonstrate CIC::DUX4 fusion and show similar histopathology to Ewing sarcomas, though lesions mimicking vascular neoplasms have recently been described. Here, we describe a case of a patient with CIC::DUX4 fusion sarcoma identified using RNA-based molecular testing who was initially diagnosed with an endothelial neoplasm. The tumor showed extensive vasoformative growth, complete WT1 negativity, and global positive staining for ERG, CD31, and DUX4 by immunohistochemistry. Methylation testing of the tumor clustered more closely with angiosarcomas than with CIC-rearranged sarcomas. Our findings suggest that CIC::DUX4 fused neoplasms may demonstrate a more diverse phenotypic range than previously appreciated and offer evidence that both molecular and immunohistochemical studies are needed for accurate diagnosis.

Keywords: CIC; CIC‐rearranged; ETV4; angiosarcoma; sarcoma.

PubMed Disclaimer

References

REFERENCES

    1. Richkind KE, Romansky SG, Finklestein JZ. t(4;19)(q35;q13.1): a recurrent change in primitive mesenchymal tumors? Cancer Genet Cytogenet. 1996;87(1):71‐74. doi:10.1016/0165‐4608(95)00240‐5
    1. Yoshimoto T, Tanaka M, Homme M, et al. CIC‐DUX4 induces small round cell sarcomas distinct from Ewing sarcoma. Cancer Res. 2017;77(11):2927‐2937. doi:10.1158/0008‐5472.CAN‐16‐3351
    1. Kawamura‐Saito M, Yamazaki Y, Kaneko K, et al. Fusion between CIC and DUX4 up‐regulates PEA3 family genes in Ewing‐like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006;15(13):2125‐2137. doi:10.1093/hmg/ddl136
    1. Okimoto RA, Wu W, Nanjo S, et al. CIC‐DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019;129(8):3401‐3406. doi:10.1172/JCI126366
    1. Smith SC, Buehler D, Choi EY, et al. CIC‐DUX sarcomas demonstrate frequent MYC amplification and ETS‐family transcription factor expression. Mod Pathol. 2015;28(1):57‐68. doi:10.1038/modpathol.2014.83

Publication types

LinkOut - more resources